Sutro Biopharma, Inc. (STRO)
NASDAQ: STRO · Real-Time Price · USD
34.87
+1.28 (3.81%)
At close: Apr 28, 2026, 4:00 PM EDT
34.69
-0.18 (-0.52%)
After-hours: Apr 28, 2026, 4:10 PM EDT
Sutro Biopharma Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Revenue | 102.48 | 62.04 | 153.73 | 67.77 | 61.88 | |
| Revenue Growth (YoY) | 65.18% | -59.64% | 126.84% | 9.52% | 44.84% | |
| Cost of Revenue | 166.42 | 252.04 | 180.43 | 137.17 | 104.4 | |
| Gross Profit | -63.93 | -190 | -26.69 | -69.4 | -42.52 | |
| Selling, General & Admin | 41.02 | 48.45 | 62.58 | 59.54 | 56 | |
| Operating Expenses | 41.02 | 48.45 | 62.58 | 59.54 | 56 | |
| Operating Income | -104.95 | -238.45 | -89.28 | -128.94 | -98.52 | |
| Interest Expense | -42.06 | -31.07 | -23.75 | -7.42 | -3.2 | |
| Interest & Investment Income | 9.25 | 18.64 | 14.51 | 3.46 | 0.58 | |
| Other Non Operating Income (Expenses) | - | -6.32 | - | - | 0.06 | |
| EBT Excluding Unusual Items | -137.76 | -257.2 | -98.52 | -132.91 | -101.08 | |
| Merger & Restructuring Charges | -53.42 | - | - | - | - | |
| Gain (Loss) on Sale of Investments | - | 32.1 | 9.92 | 16.2 | -4.45 | |
| Pretax Income | -191.18 | -225.1 | -88.6 | -116.7 | -105.54 | |
| Income Tax Expense | -0.09 | 2.36 | 18.19 | 2.5 | - | |
| Net Income | -191.09 | -227.46 | -106.79 | -119.2 | -105.54 | |
| Net Income to Common | -191.09 | -227.46 | -106.79 | -119.2 | -105.54 | |
| Shares Outstanding (Basic) | 8 | 8 | 6 | 5 | 5 | |
| Shares Outstanding (Diluted) | 8 | 8 | 6 | 5 | 5 | |
| Shares Change (YoY) | 9.84% | 28.59% | 18.57% | 10.02% | 41.59% | |
| EPS (Basic) | -22.49 | -29.40 | -17.75 | -23.49 | -22.88 | |
| EPS (Diluted) | -22.49 | -29.40 | -17.75 | -23.49 | -22.88 | |
| Free Cash Flow | -178.93 | -194.64 | -115.93 | -4.31 | -97 | |
| Free Cash Flow Per Share | -21.06 | -25.16 | -19.27 | -0.85 | -21.03 | |
| Gross Margin | -62.38% | - | -17.36% | -102.40% | -68.71% | |
| Operating Margin | -102.41% | -384.33% | -58.07% | -190.26% | -159.22% | |
| Profit Margin | -186.45% | -366.62% | -69.47% | -175.89% | -170.55% | |
| Free Cash Flow Margin | -174.59% | -313.72% | -75.41% | -6.36% | -156.76% | |
| EBITDA | -97.63 | -231.24 | -82.46 | -123.25 | -93.68 | |
| EBITDA Margin | -95.26% | - | -53.64% | -181.86% | -151.39% | |
| D&A For EBITDA | 7.32 | 7.22 | 6.82 | 5.69 | 4.84 | |
| EBIT | -104.95 | -238.45 | -89.28 | -128.94 | -98.52 | |
| EBIT Margin | -102.41% | - | -58.07% | -190.26% | -159.22% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.